Trastuzumab Deruxtecan 100mg Infusion$2,128.00
1–9 boxes
$2,128.00 each
10–24 boxes
8% off
25+ boxes
10% off
Trastuzumab Deruxtecan 100mg Infusion
SKU GME1340Oncology Care
Product Introduction
Trastuzumab Deruxtecan 100mg is a HER2-directed antibody–drug conjugate for selected HER2-expressing cancers. Eligibility depends on the tumour type, HER2 assessment and prior treatment.
How to use
The vial is reconstituted, diluted in the compatible infusion fluid and administered intravenously. The initial infusion is slower than later tolerated infusions. Antiemetic prophylaxis is part of the regimen. It is not an intravenous push.
How it works
The antibody binds HER2 and delivers a topoisomerase-I inhibitor into the tumour cell, causing DNA damage. Released payload can also affect nearby tumour cells.
Side effects
Nausea, vomiting, fatigue, hair loss and low blood counts can occur. Interstitial lung disease or pneumonitis and reduced heart function are important serious risks.
Important information
Report any new cough, fever or breathlessness immediately. HER2 testing, blood counts and cardiac assessment guide treatment. It is distinct from unconjugated trastuzumab and trastuzumab emtansine.
Uses
- Selected HER2-expressing breast, gastric, lung or other cancers in an established treatment setting.
Benefits
Can help control the growth of HER2-expressing tumours by delivering anticancer medicine to the target cells.
Is it the same as ordinary trastuzumab?
No. The attached cytotoxic payload changes its mechanism, dose and adverse-effect profile.
Why is a new mild cough urgent?
It can be an early sign of interstitial lung disease. Early detection can prevent progression.
Does HER2 testing always mean HER2-positive amplification?
No. Some settings use specific low-expression or mutation criteria. Eligibility depends on the exact cancer indication.
Why is anti-nausea medicine given before symptoms start?
This treatment has a substantial emetic risk, so prevention is more effective than waiting for severe vomiting.
HER2: a growth-related receptor expressed by some tumours. Antibody–drug conjugate: an antibody linked to a cytotoxic drug. Topoisomerase I: an enzyme involved in DNA processing.; AR: Trastuzumab Deruxtecan 100mg تسريب وريدي; FR: Trastuzumab Deruxtecan 100mg perfusion intraveineuse; PT: Trastuzumab Deruxtecan 100mg infusão intravenosa; ES: Trastuzumab Deruxtecan 100mg perfusión intravenosa; RU: Trastuzumab Deruxtecan 100mg внутривенная инфузия; ID: Trastuzumab Deruxtecan 100mg infus intravena; VI: Trastuzumab Deruxtecan 100mg thuốc truyền tĩnh mạch; MS: Trastuzumab Deruxtecan 100mg infusi intravena; TL: Trastuzumab Deruxtecan 100mg pagbubuhos sa ugat; ZH-SG: Trastuzumab Deruxtecan 100mg 静脉输注